Northern Trust’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-27,778
| Closed | -$73.9K | – | 4523 |
|
|
2024
Q1 | $73.9K | Hold |
27,778
| – | – | ﹤0.01% | 4153 |
|
|
2023
Q4 | $65.8K | Hold |
27,778
| – | – | ﹤0.01% | 4185 |
|
|
2023
Q3 | $38.9K | Sell |
27,778
-231
| -0.8% | -$555 | ﹤0.01% | 4226 |
|
|
2023
Q2 | $84.9K | Sell |
28,009
-183,846
| -87% | -$709K | ﹤0.01% | 4081 |
|
|
2023
Q1 | $1.32M | Sell |
211,855
-2,961
| -1% | -$18K | ﹤0.01% | 3116 |
|
|
2022
Q4 | $1.31M | Sell |
214,816
-5,808
| -3% | -$47.3K | ﹤0.01% | 3171 |
|
|
2022
Q3 | $2.64M | Sell |
220,624
-4,982
| -2% | -$65.2K | ﹤0.01% | 2863 |
|
|
2022
Q2 | $2.85M | Buy |
225,606
+17,769
| +9% | +$165K | ﹤0.01% | 2858 |
|
|
2022
Q1 | $2.34M | Sell |
207,837
-5,700
| -3% | -$62.7K | ﹤0.01% | 3019 |
|
|
2021
Q4 | $3.78M | Buy |
213,537
+2,184
| +1% | +$46.1K | ﹤0.01% | 2865 |
|
|
2021
Q3 | $4.87M | Buy |
211,353
+75,840
| +56% | +$1.65M | ﹤0.01% | 2749 |
|
|
2021
Q2 | $3.15M | Sell |
135,513
-10,095
| -7% | -$257K | ﹤0.01% | 3122 |
|
|
2021
Q1 | $4.54M | Buy |
+145,608
| New | +$5.07M | ﹤0.01% | 2817 |
|
Northern Trust's KNTE Position: Q2 2024 in Review
Northern Trust sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2024, closing a stake of 27,778 shares — an estimated $73.9K sold.
Northern Trust first reported a position in KNTE in Q1 2021 and held it in 13 quarters. The position peaked at $4.87M in Q3 2021. 0 funds tracked by Wall St. Rank hold KNTE as of Q2 2024.
- Northern Trust reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Northern Trust sold 27,778 Kinnate Biopharma Inc. Common Stock shares in Q2 2024, an estimated $73.9K.
- Northern Trust first reported a position in Kinnate Biopharma Inc. Common Stock in Q1 2021 and held it in 13 quarters.
- Northern Trust's Kinnate Biopharma Inc. Common Stock position peaked at $4.87M in Q3 2021.
- 0 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2024.
Based on Northern Trust's 13F filing for Q2 2024, filed 14 Aug 2024.